UK’s competition body begins full scale investigation into Illumina, Pacific Biosciences merger

Competition and Markets Authority

UK’s Competition and Markets Authority (CMA), said it will begin a full-scale investigation into the merger between Illumina Inc and Pacific Biosciences of California Inc.

The merger was estimated at $1.2 billion.

The antitrust agency said it will refer the merger to a second phase investigation because Illumina Inc and Pacific Biosciences did not address concerns raised by CMA.

The CMA had complained that the merger could negatively affect the supply of specialist DNA sequencing systems in the UK.